Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'HIGH-DOSE INTERLEUKIN-2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 270 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Pappo, I; Lotem, M; Klein, M; Orda, R
      Bolus high dose interleukin-2 for the treatment of malignant melanoma

      ISRAEL MEDICAL ASSOCIATION JOURNAL
    2. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials

      MEDICAL ONCOLOGY
    3. Alvarnas, JC; Linn, YC; Hope, EG; Negrin, RS
      Expansion of cytotoxic CD3(+)CD56(+) cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    4. Buzaid, AC; Atkins, M
      Practical guidelines for the management of biochemotherapy-related toxicity in melanoma

      CLINICAL CANCER RESEARCH
    5. Takeuchi, E; Yanagawa, H; Suzuki, Y; Shinkawa, K; Bando, H; Sone, S
      Interleukin (IL-)15 has less activity than IL-2 to promote type 2 cytokinepredominance in tumour-associated mononuclear cells from lung cancer patients

      CYTOKINE
    6. Kaufman, HL; DeRaffele, G; Divito, J; Horig, H; Lee, D; Panicali, D; Voulo, M
      A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma

      HUMAN GENE THERAPY
    7. Heinzer, H; Huland, E; Huland, H
      Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

      WORLD JOURNAL OF UROLOGY
    8. Malaguarnera, L; Ferlito, L; Di Mauro, S; Imbesi, RM; Scalia, G; Malaguarnera, M
      Immunosenescence and cancer: a review

      ARCHIVES OF GERONTOLOGY AND GERIATRICS
    9. Malaguarnera, M; Ferlito, L; Gulizia, G; Di Fazio, I; Pistone, G
      Use of interleukin-2 in advanced renal carcinoma: meta-analysis and reviewof the literature

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    10. Elias, L; Hunt, WC
      A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy

      ONCOLOGY
    11. Chi, KH; Myers, JN; Chow, KC; Chan, WK; Tsang, YW; Chao, Y; Yen, SH
      Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma

      ONCOLOGY
    12. Rosenberg, SA
      Progress in human tumour immunology and immunotherapy

      NATURE
    13. Vasselli, JR; Yang, JC; Linehan, WM; White, DE; Rosenberg, SA; Walther, MM
      Lack of retroperitoneal lymphadenopathy predicts survival of patients withmetastatic renal cell carcinoma

      JOURNAL OF UROLOGY
    14. Deshmukh, P; Glick, RP; Lichtor, T; Moser, R; Cohen, EP
      Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice

      JOURNAL OF NEUROSURGERY
    15. Pizza, G; De Vinci, C; Lo Conte, G; Maver, P; Dragoni, E; Aiello, E; Fornarola, V; Bergami, T; Busutti, L; Boriani, S; Palareti, A; Capanna, R
      Immunotherapy of metastatic kidney cancer

      INTERNATIONAL JOURNAL OF CANCER
    16. Ravaud, A
      Cell therapy for solid tumors

      BULLETIN DU CANCER
    17. Su, H; Lu, RH; Ding, RX; Kan, YW
      Adeno-associated viral-mediated gene transfer to hepatoma: Thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals

      MOLECULAR THERAPY
    18. Frohn, C; Doehn, C; Durek, C; Bohle, A; Schlenke, P; Jocham, D; Kirchner, H
      Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma

      JOURNAL OF IMMUNOTHERAPY
    19. Marroquin, CE; White, DE; Steinberg, SM; Rosenberg, SA; Schwartzentruber, DJ
      Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer

      JOURNAL OF IMMUNOTHERAPY
    20. deMagalhaes-Silverman, M; Donnenberg, A; Lembersky, B; Elder, E; Lister, J; Rybka, W; Whiteside, T; Ball, E
      Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

      JOURNAL OF IMMUNOTHERAPY
    21. Mekhail, T; Wood, L; Bukowski, R
      Interleukin-2 in cancer therapy - Uses and optimum management of adverse effects

      BIODRUGS
    22. Frost, P; Bonavida, B
      Circumvention of tumor cell escape following specific immunotherapy

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    23. Atkins, MB
      Interleukin-2 in metastatic melanoma: What is the current role?

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    24. Negrier, S; Maral, J; Drevon, M; Vinke, J; Escudier, B; Philip, T
      Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe

      CANCER JOURNAL FROM SCIENTIFIC AMERICAN
    25. Dutcher, JP; Logan, T; Gordon, M; Sosman, J; Weiss, G; Margolin, K; Plasse, T; Mier, J; Lotze, M; Clark, J; Atkins, M
      Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study

      CLINICAL CANCER RESEARCH
    26. Visonneau, S; Cesano, A; Porter, DL; Luger, SL; Schuchter, L; Kamoun, M; Torosian, MH; Duffy, K; Sickles, C; Stadtmauer, EA; Santoli, D
      Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer

      CLINICAL CANCER RESEARCH
    27. Kaplan, B; Moy, RL
      Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma

      DERMATOLOGIC SURGERY
    28. Motoi, F; Sunamura, M; Ding, LH; Duda, DG; Yoshida, Y; Zhang, WP; Matsuno, S; Hamada, H
      Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus

      HUMAN GENE THERAPY
    29. Locker, GJ; Stoiser, B; Losert, H; Wenzel, C; Ohler, L; Kabrna, E; Geissler, K
      Decrease of circulating hematopoietic progenitor cells during interleukin-2 treatment is associated with an increase of vascular cell adhesion molecule-1, a critical molecule for progenitor cell adhesion

      LEUKEMIA & LYMPHOMA
    30. Bremers, AJA; Parmiani, G
      Immunology and immunotherapy of human cancer: present concepts and clinical developments

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    31. Schmidt, H; Geertsen, PF; Fode, K; Rytter, C; Bastholt, L; von der Maase, H
      Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study

      MELANOMA RESEARCH
    32. Daly, T; Royal, RE; Kershaw, MH; Treisman, J; Wang, G; Li, WP; Herlyn, D; Eshhar, Z; Hwu, P
      Recognition of human colon cancer by T cells transduced with a chimeric receptor gene

      CANCER GENE THERAPY
    33. Yaniv, I
      Lymphokines post autologous peripheral blood stem cell transplantation in children

      PEDIATRIC HEMATOLOGY AND ONCOLOGY
    34. Bremers, AJA; Kuppen, PJK; Parmiani, G
      Tumour immunotherapy: the adjuvant treatment of the 21st century?

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    35. Negrier, S; Caty, A; Lesimple, T; Douillard, JY; Escudier, B; Rossi, JF; Viens, P; Gomez, F
      Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil

      JOURNAL OF CLINICAL ONCOLOGY
    36. Schmidinger, M; Steger, GG; Wenzel, C; Locker, GJ; Brodowicz, T; Budinsky, AC; Wiltschke, C; Kramer, G; Marberger, M; Zielinski, CC
      Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: results of a phase II trial

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    37. Hagenaars, M; Ensink, NG; Eggermont, AMM; van der Velde, EA; van de Velde, CJH; Fleuren, GJ; Kuppen, PJK
      Endogenous natural killer cells do not play a role in antitumor effects induced by interleukin-2 in a syngeneic rat colon tumor model

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    38. Vasey, PA
      Immunotherapy for renal carcinoma: theoretical basis and current standard of care

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    39. Bonig, H; Laws, HJ; Wundes, A; Verheyen, J; Hannen, M; Kim, YM; Banning, U; Nurnberger, W; Korholz, D
      In vivo cytokine responses to interleukin-2 immunotherapy after autologousstem cell transplantation in children with solid tumors

      BONE MARROW TRANSPLANTATION
    40. Edington, H; Agarwala, S; Kirkwood, JM
      Biologic therapy

      CLINICS IN PLASTIC SURGERY
    41. Margolin, KA
      Interleukin-2 in the treatment of renal cancer

      SEMINARS IN ONCOLOGY
    42. Morse, MA; Lyerly, HK
      Dendritic cell-based immunization for cancer therapy

      CANCER GENE THERAPY
    43. Keilholz, U; Eggermont, AMM
      The emerging role of cytokines in the treatment of advanced melanoma

      ONCOLOGY
    44. Maxwell-Armstrong, CA; Scholefield, JH
      Current perspectives on immunotherapy for colorectal cancer

      DRUGS OF TODAY
    45. Kawagoe, N; Shintaku, I; Yutani, S; Etoh, H; Matuoka, K; Noda, S; Itoh, K
      Expression of the SART3 tumor rejection antigen in renal cell carcinoma

      JOURNAL OF UROLOGY
    46. Motzer, RJ; Russo, P
      Systemic therapy for renal cell carcinoma

      JOURNAL OF UROLOGY
    47. Multhoff, G; Pfister, K; Botzler, C; Jordan, A; Scholz, R; Schmetzer, H; Burgstahler, R
      Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors

      INTERNATIONAL JOURNAL OF CANCER
    48. Ioannou, Y; Isenberg, DA
      Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

      ARTHRITIS AND RHEUMATISM
    49. Monsuez, JJ; Gallet, B; Escaut, L; Vayre, F; Pulik, M; Charniot, JC; Merad, M; Slama, M; Weber, S; Vittecoq, D
      Cardiac side-effects of drugs used to treat HIV infection.

      ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
    50. Hernberg, M; Pyrhonen, S; Muhonen, T
      Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials

      JOURNAL OF IMMUNOTHERAPY
    51. Kim, CJ; Chan, CC; Rosenberg, SA
      Ophthalmologic evaluation in patients undergoing immunization with melanoma-associated antigens

      JOURNAL OF IMMUNOTHERAPY
    52. Agarwala, SS; Kirkwood, JM
      Melanoma - Immunotherapeutic approaches

      BIODRUGS
    53. Kammula, US; Marincola, FM
      Cancer immunotherapy: Is there real progress at last?

      BIODRUGS
    54. Vannier, E; Kaser, A; Atkins, MB; Fantuzzi, G; Dinarello, CA; Mier, JW; Tilg, H
      Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy

      EUROPEAN CYTOKINE NETWORK
    55. Queirolo, P; Ponte, M; Gipponi, M; Cafiero, F; Peressini, A; Semino, C; Pietra, G; Lionetto, R; Vecchio, S; Ribizzi, I; Melioli, G; Sertoli, MR
      Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase III pilot trial

      ANNALS OF SURGICAL ONCOLOGY
    56. Morse, MA; Lyerly, HK
      Cellular and biological therapies of gastrointestinal tumors: Overview of clinical trials

      ANNALS OF SURGICAL ONCOLOGY
    57. Garcia, ED; Santolaya, R; Requena, T
      Treatment of malignant melanoma

      ANNALS OF PHARMACOTHERAPY
    58. Schreiber, S; Kampgen, E; Wagner, E; Pirkhammer, D; Trcka, J; Korschan, H; Lindemann, A; Dorffner, R; Kittler, H; Kasteliz, F; Kupcu, Z; Sinski, A; Zatloukal, K; Buschle, M; Schmidt, W; Birnstiel, M; Kempe, RE; Voigt, T; Weber, HA; Pehamberger, H; Mertelsmann, R; Brocker, EB; Wolff, K; Stingl, G
      Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2 transfected cancer cells: Outcome of a phase I study

      HUMAN GENE THERAPY
    59. Kim, JH; Gong, SJ; Yoo, NC; Lee, H; Shin, DH; Uhm, HD; Jeong, SJ; Cho, JY; Rha, SY; Kim, YS; Chung, HC; Roh, JK; Min, JS; Kim, BS
      Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector

      ONCOLOGY REPORTS
    60. Escudier, B; Chevreau, C; Lasset, C; Douillard, JY; Ravaud, A; Fabbro, M; Caty, A; Rossi, JF; Viens, P; Bergerat, JP; Savary, J; Negrier, S
      Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?

      JOURNAL OF CLINICAL ONCOLOGY
    61. Heinzer, H; Mir, TS; Huland, E; Huland, H
      Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy

      JOURNAL OF CLINICAL ONCOLOGY
    62. Heinzer, H; Huland, E; Aalamian, M; Huland, H
      Treatment of pulmonary metastases from kidney cell carcinoma with inhalational interleukin-2. 10-year experience Hamburger Unicenter

      UROLOGE-AUSGABE A
    63. Hautmann, SH; Huland, E; Huland, H
      Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth

      ANTICANCER RESEARCH
    64. Huland, E; Heinzer, H; Huland, H
      Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)

      ANTICANCER RESEARCH
    65. Strohmaier, WL
      New treatment modalities - The urologist's view

      ANTICANCER RESEARCH
    66. Lygidakis, NJ; Safioleas, M; Sgourakis, G; Spentzouris, N; Dedemadi, G; Sotiropoulou, P
      Metastatic melanoma: Transplenic immunostimulation - A new therapeutical alternative for an ever-challenging disease

      HEPATO-GASTROENTEROLOGY
    67. Huland, E; Heinzer, H; Huland, H
      Immunotherapy of pulmonary metastatic renal cell carcinoma: Success dependant on risk factors?

      HEPATO-GASTROENTEROLOGY
    68. Caturla, JT; Soler, RS; Larriba, JLG
      Immunological treatment of renal cancer

      MEDICINA CLINICA
    69. Wagner, JR; Walther, MM; Linehan, WM; White, DE; Rosenberg, SA; Yang, JC
      Interleukin-2 based immunotherapy for metastatic renal cell carcinoma withthe kidney in place

      JOURNAL OF UROLOGY
    70. Lum, LG
      T cell-based immunotherapy for cancer: A virtual reality?

      CA-A CANCER JOURNAL FOR CLINICIANS
    71. Maxwell-Armstrong, CA; Durrant, LG; Scholefield, JH
      Immunotherapy for colorectal cancer

      AMERICAN JOURNAL OF SURGERY
    72. HARTHUN NL; WEAVER AM; BRINCKERHOFF LH; DEACON DH; GONIAS SL; SLINGLUFF CL
      ACTIVATED ALPHA(2)-MACROGLOBULIN REVERSES THE IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN BREAST-CANCER CELL-CONDITIONED MEDIUM BY SELECTIVELY NEUTRALIZING TRANSFORMING-GROWTH-FACTOR-BETA IN THE PRESENCE OF INTERLEUKIN-2

      Journal of immunotherapy
    73. ALTERS SE; GADEA JR; SORICH M; ODONOGHUE G; TALIB S; PHILIP R
      DENDRITIC CELLS PULSED WITH CEA PEPTIDE INDUCE CEA-SPECIFIC CTL WITH RESTRICTED TCR REPERTOIRE

      Journal of immunotherapy
    74. ESCUDIER B; RAVAUD A; BERTON D; CHEVREAU C; DOUILLARD JY; DIETRICH PY
      PHASE-II STUDY OF INTERFERON-ALPHA AND ALL-TRANS-RETINOIC ACID IN METASTATIC RENAL-CELL CARCINOMA

      Journal of immunotherapy
    75. Fleckenstein, G; Osmers, R; Puchta, J
      Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer

      MEDICAL ONCOLOGY
    76. PROVINCIALI M; DISTEFANO G; STRONATI S; FABRIS N
      GENERATION OF HUMAN LYMPHOKINE-ACTIVATED KILLER-CELLS FOLLOWING AN IL-2 PULSE IN ELDERLY CANCER-PATIENTS

      Cytokine
    77. STOPECK AT; HERSH EM; BRAILEY JL; CLARK PR; NORMAN J; PARKER SE
      TRANSFECTION OF PRIMARY TUMOR-CELLS AND TUMOR-CELL LINES WITH PLASMIDDNA LIPID COMPLEXES/

      Cancer gene therapy
    78. ATKINS MB
      IMMUNOTHERAPY AND EXPERIMENTAL APPROACHES FOR METASTATIC MELANOMA

      Hematology/oncology clinics of North America
    79. KEILHOLZ U; CONRADT C; LEGHA SS; KHAYAT D; SCHEIBENBOGEN C; THATCHER N; GOEY SH; GORE M; DORVAL T; HANCOCK B; PUNT CJA; DUMMER R; AVRIL MF; BROCKER EB; BENHAMMOUDA A; EGGERMONT AMM; PRITSCH M
      RESULTS OF INTERLEUKIN-2-BASED TREATMENT IN ADVANCED MELANOMA - A CASE RECORD-BASED ANALYSIS OF 631 PATIENTS

      Journal of clinical oncology
    80. TOURANI JM; PFISTER C; BERDAH JF; BENHAMMOUDA A; SALZE P; MONNIER A; PAULE B; GUILLET P; CHRETIEN Y; BREWER Y; DIPALMA M; UNTEREINER M; MALAURIE E; TADRIST Z; PAVLOVITCH JM; HAUTEVILLE D; MEJEAN A; AZAGURY M; MAYEUR D; LUCAS V; KRAKOWSKI I; LARREGAINFOURNIER D; ABOURACHID H; ANDRIEU JM; CHASTANG C
      OUTPATIENT TREATMENT WITH SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA ADMINISTRATION IN COMBINATION WITH FLUOROURACIL IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - RESULTS OF A SEQUENTIAL NONRANDOMIZED-PHASE-II STUDY

      Journal of clinical oncology
    81. STADLER WM; KUZEL T; DUMAS M; VOGELZANG NJ
      MULTICENTER PHASE-II TRIAL OF INTERLEUKIN-2, INTERFERON-ALPHA, AND 13-CIS-RETINOIC ACID IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

      Journal of clinical oncology
    82. NAGLIERI E; GEBBIA V; DURINI E; LELLI G; ABBATE I; SELVAGGI FP; DITONNO P; COLUCCI G
      STANDARD INTERLEUKIN-2 (IL-2) AND INTERFERON-ALPHA IMMUNOTHERAPY VERSUS AN IL-2 AND 4-EPIRUBICIN IMMUNO-CHEMOTHERAPEUTIC ASSOCIATION IN METASTATIC RENAL-CELL CARCINOMA

      Anticancer research
    83. ORUCEVIC A; LALA PK
      ROLE OF NITRIC-OXIDE IN IL-2 THERAPY-INDUCED CAPILLARY LEAK SYNDROME

      Cancer metastasis reviews
    84. VOGELZANG NJ; STADLER WM
      KIDNEY CANCER

      Lancet
    85. TRUICA CI; HANSEN CH; GARVIN DF; MEEHAN KR
      IDIOPATHIC GIANT-CELL MYOCARDITIS AFTER AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION AND INTERLEUKIN-2 IMMUNOTHERAPY - A CASE-REPORT

      Cancer
    86. RAAD II; HACHEM RY; ABISAID D; ROLSTON KVI; WHIMBEY E; BUZAID AC; LEGHA S
      A PROSPECTIVE CROSSOVER RANDOMIZED TRIAL OF NOVOBIOCIN AND RIFAMPIN PROPHYLAXIS FOR THE PREVENTION OF INTRAVASCULAR CATHETER INFECTIONS IN CANCER-PATIENTS TREATED WITH INTERLEUKIN-2

      Cancer
    87. DELORD JP; ALEXANDRE J; CHEVREAU C; ESCUDIER B
      ADULT RENAL-CELL CARCINOMA

      Bulletin du cancer
    88. REYA T; CONTRACTOR NV; COUZENS MS; WASIK MA; EMERSON SG; CARDING SR
      ABNORMAL MYELOCYTIC CELL-DEVELOPMENT IN INTERLEUKIN-2 (IL-2)-DEFICIENT MICE - EVIDENCE FOR THE INVOLVEMENT OF IL-2 IN MYELOPOIESIS

      Blood
    89. MORSE MA; LYERLY HK
      IMMUNOTHERAPY OF CANCER USING DENDRITIC CELLS

      Cytokines cellular & molecular therapy
    90. HANSSON J
      SYSTEMIC THERAPY OF MALIGNANT-MELANOMA

      Medical oncology
    91. DILLMAN RO; CRISPIN R; OLDHAM RK
      THE CANCER-BIOTHERAPY-RESEARCH-GROUP [CBRG], FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP [NBSG] - A 10-YEAR PERSPECTIVE

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    92. DUTCHER JP; FISHER RI; WEISS G; ARONSON F; MARGOLIN K; LOUIE A; MIER J; CALIENDO G; SOSMAN JA; ECKARDT JR; ERNEST M; DOROSHOW J; ATKINS M
      OUTPATIENT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA FOR METASTATIC RENAL-CELL CANCER - 5-YEAR FOLLOW-UP OF THE CYTOKINE WORKING GROUP-STUDY

      The cancer journal from Scientific American
    93. KEILHOLZ U; STOTER G; PUNT CJA; SCHEIBENBOGEN C; LEJEUNE F; EGGERMONT AMM
      RECOMBINANT INTERLEUKIN-2-BASED TREATMENTS FOR ADVANCED MELANOMA - THE EXPERIENCE OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER MELANOMA COOPERATIVE GROUP

      The cancer journal from Scientific American
    94. HULAND E; HEINZER H; MIR TS; HULAND H
      INHALED INTERLEUKIN-2 THERAPY IN PULMONARY METASTATIC RENAL-CELL CARCINOMA - 6 YEARS OF EXPERIENCE

      The cancer journal from Scientific American
    95. BUKOWSKI RM; OLENCKI T; WANG Q; PEEREBOOM D; BUDD GT; ELSON P; SANDSTROM K; TUASON L; RAYMAN P; TUBBS R; MCLAIN D; KLEIN E; NOVICK A; FINKE J
      PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE

      Journal of immunotherapy with emphasis on tumor immunology
    96. REDDY SP; HARWOOD RM; MOORE DF; GRIMM EA; MURRAY JL; VADHANRAJ S
      RECOMBINANT INTERLEUKIN-2 IN COMBINATION WITH RECOMBINANT INTERFERON-GAMMA IN PATIENTS WITH ADVANCED MALIGNANCY - A PHASE-1 STUDY

      Journal of immunotherapy with emphasis on tumor immunology
    97. MASUCCI G; SVENSSON A; HANSSON M; HANSSON J; NAKAZAWA T; SALAZAR F; PETERSSON M; KIESSLING R
      EFFICIENT HARVEST OF IN-VIVO IL-2-ACTIVATED CD3+ LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY BY SELECTIVE LEUKAPHERESIS (LYMPHOCYTAPHERESIS)

      Journal of hematotherapy
    98. DRANOFF G; SOIFFER R; LYNCH T; MIHM M; JUNG K; KOLESAR K; LIEBSTER L; DUDA R; MENTZER S; SINGER S; TANABE K; JOHNSON R; SOBER A; BHAN A; CLIFT S; COHEN L; PARRY G; ROKOVICH J; RICHARDS L; DRAYER J; BERNS A; MULLIGAN RC
      A PHASE-I STUDY OF VACCINATION WITH AUTOLOGOUS, IRRADIATED MELANOMA-CELLS ENGINEERED TO SECRETE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

      Human gene therapy
    99. DOUCET C; MEAZZA R; POTTINCLEMENCEAU C; SCUDELETTI M; BROUTYBOYE D; FERRINI S; ALILECHE A; TAOUFIK Y; JASMIN C; AZZARONE B; INDIVERI F
      ROLE OF INTERLEUKIN (IL)-2 AND IL-15 IN THE TUMOR PROGRESSION OF A MELANOMA CELL-LINE MELP, DERIVED FROM AN IL-2 PROGRESSOR PATIENT

      Melanoma research
    100. NAGASHIMA S; REICHERT TE; KASHII Y; SUMINAMI Y; CHIKAMATSU K; WHITESIDE TL
      IN-VITRO AND IN-VIVO CHARACTERISTICS OF HUMAN SQUAMOUS-CELL CARCINOMAOF THE HEAD AND NECK CELLS ENGINEERED TO SECRETE INTERLEUKIN-2

      Cancer gene therapy


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 07:21:08